AbbVie to unveil new solid‑tumor data on seven oncology assets at ESMO 2026
AbbVie announced that it will present updated clinical and biomarker data on seven investigational and approved oncology assets at the European Society for Medical Oncology Congress in Madrid, Oct. 23‑27, 2026. The disclosures include a 30% overall response rate for Temab‑A in colorectal cancer and a 50% response in non‑small‑cell lung cancer, a 56% response for ABBV‑706 in small‑cell lung cancer, and a 90% ctDNA reduction for ABBV‑969 in metastatic castration‑resistant prostate cancer. The company highlighted these results as evidence of longer‑term benefit and the potential of next‑generation ADC and bispecific platforms.
Why it matters
The company says the data reinforce its biology‑driven oncology strategy and could boost investor confidence in the pipeline’s commercial potential. Analysts will watch the forthcoming ESMO presentations for signals that may affect future revenue forecasts and valuation.
Key facts
- 1AbbVie will present data at the 2026 ESMO Congress in Madrid, Spain, from Oct. 23‑27. news.abbvie.com
- 2The ESMO program will feature seven assets across lung, colorectal, ovarian, prostate and gastric cancers. news.abbvie.com
- 3Temab‑A (2.4 mg/kg) plus bevacizumab showed a 30% overall response rate in a Phase 1 colorectal cancer cohort (n=30). news.abbvie.com
- 4In a Phase 1 study of Temab‑A in non‑squamous NSCLC, the overall response rate was 50% (n=48). gurufocus.com
- 5ABBV‑706 achieved a 56% overall response rate at the selected Phase 3 dose of 1.8 mg/kg in relapsed/refractory small‑cell lung cancer (n=41). gurufocus.com
- 6ABBV‑969 produced a ≥50% reduction in circulating tumor DNA in 90% of heavily pretreated metastatic castration‑resistant prostate cancer patients (n=49) by cycle 3. gurufocus.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.